Gilead wins US OK for Viread tablet, powder formulations for children
This article was originally published in Scrip
Executive Summary
Gilead Sciences gained the US FDA's blessing to market the firm's HIV drug Viread (tenofovir disoproxil fumarate) in the US as a treatment in combination with other antiretroviral agents for children as young as 2 years.